 Receptor, PAR-1
"Receptor, PAR-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A thrombin receptor subtype that couples to HETEROTRIMERIC GTP-BINDING PROTEINS resulting in the activation of a variety of signaling mechanisms including decreased intracellular CYCLIC AMP, increased TYPE C PHOSPHOLIPASES and increased PHOSPHOLIPASE A2.
| Descriptor ID |
D044463
|
| MeSH Number(s) |
D12.776.395.550.625.800.790 D12.776.543.550.625.800.790 D12.776.543.750.695.875.500 D12.776.543.750.705.675.892.790 D12.776.543.750.750.850.399 D12.776.543.750.792.500.500
|
| Concept/Terms |
Receptor, PAR-1- Receptor, PAR-1
- Receptor, PAR 1
- PAR1 Receptor
- Receptor, PAR1
- Protease-Activated Receptor 1
- Protease Activated Receptor 1
- PAR-1 Receptor
- PAR 1 Receptor
- Proteinase-Activated Receptor 1
- Proteinase Activated Receptor 1
|
Below are MeSH descriptors whose meaning is more general than "Receptor, PAR-1".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Glycoproteins [D12.776.395]
- Membrane Glycoproteins [D12.776.395.550]
- Platelet Membrane Glycoproteins [D12.776.395.550.625]
- Receptors, Thrombin [D12.776.395.550.625.800]
- Receptor, PAR-1 [D12.776.395.550.625.800.790]
- Membrane Proteins [D12.776.543]
- Membrane Glycoproteins [D12.776.543.550]
- Platelet Membrane Glycoproteins [D12.776.543.550.625]
- Receptors, Thrombin [D12.776.543.550.625.800]
- Receptor, PAR-1 [D12.776.543.550.625.800.790]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Thrombin [D12.776.543.750.695.875]
- Receptor, PAR-1 [D12.776.543.750.695.875.500]
- Receptors, Immunologic [D12.776.543.750.705]
- Platelet Membrane Glycoproteins [D12.776.543.750.705.675]
- Receptors, Thrombin [D12.776.543.750.705.675.892]
- Receptor, PAR-1 [D12.776.543.750.705.675.892.790]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Thrombin [D12.776.543.750.750.850]
- Receptor, PAR-1 [D12.776.543.750.750.850.399]
- Receptors, Proteinase-Activated [D12.776.543.750.792]
- Receptors, Thrombin [D12.776.543.750.792.500]
- Receptor, PAR-1 [D12.776.543.750.792.500.500]
Below are MeSH descriptors whose meaning is more specific than "Receptor, PAR-1".
This graph shows the total number of publications written about "Receptor, PAR-1" by people in this website by year, and whether "Receptor, PAR-1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2009 | 4 | 0 | 4 | | 2012 | 3 | 0 | 3 | | 2013 | 1 | 1 | 2 | | 2015 | 1 | 1 | 2 | | 2016 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, PAR-1" by people in Profiles.
-
Priestley ES, Banville J, Deon D, Dub? L, Gagnon M, Guy J, Lapointe P, Lavall?e JF, Martel A, Plamondon S, R?millard R, Ruediger E, Tremblay F, Posy SL, Guarino VR, Richter JM, Li J, Gupta A, Vetrichelvan M, Balapragalathan TJ, Mathur A, Hua J, Callejo M, Guay J, Sum CS, Cvijic ME, Watson C, Wong P, Yang J, Bouvier M, Gordon DA, Wexler RR, Marinier A. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4. J Med Chem. 2022 07 14; 65(13):8843-8854.
-
Correa S, Bonaca MP, Scirica BM, Murphy SA, Goodrich EL, Morrow DA, O'Donoghue ML. Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. J Thromb Thrombolysis. 2019 Apr; 47(3):353-360.
-
Aldrovandi M, Hinz C, Lauder SN, Podmore H, Hornshaw M, Slatter DA, Tyrrell VJ, Clark SR, Marnett LJ, Collins PW, Murphy RC, O'Donnell VB. DioxolaneA3-phosphatidylethanolamines are generated by human platelets and stimulate neutrophil integrin expression. Redox Biol. 2017 04; 11:663-672.
-
Bonaca MP, Creager MA, Olin J, Scirica BM, Gilchrist IC, Murphy SA, Goodrich EL, Braunwald E, Morrow DA. Peripheral Revascularization in Patients With?Peripheral Artery Disease With?Vorapaxar: Insights From the TRA 2?P-TIMI 50 Trial. JACC Cardiovasc Interv. 2016 10 24; 9(20):2157-2164.
-
Bohula EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murphy SA, Scirica BM, White H, Braunwald E, Morrow DA. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2?P-TIMI 50. Circulation. 2015 Nov 17; 132(20):1871-9.
-
Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KA, Murphy SA, Nicolau JC, Oude Ophuis T, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015 Mar 19; 4(3):e001505.
-
Aldrovandi M, Hammond VJ, Podmore H, Hornshaw M, Clark SR, Marnett LJ, Slatter DA, Murphy RC, Collins PW, O'Donnell VB. Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation. J Lipid Res. 2013 Nov; 54(11):3085-97.
-
Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013 Apr 09; 127(14):1522-9, 1529e1-6.
-
Morrow DA, Alberts MJ, Mohr JP, Ameriso SF, Bonaca MP, Goto S, Hankey GJ, Murphy SA, Scirica BM, Braunwald E. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013 Mar; 44(3):691-8.
-
Ahmad S, Ahmad A, Rancourt RC, Neeves KB, Loader JE, Hendry-Hofer T, Di Paola J, Reynolds SD, White CW. Tissue factor signals airway epithelial basal cell survival via coagulation and protease-activated receptor isoforms 1 and 2. Am J Respir Cell Mol Biol. 2013 Jan; 48(1):94-104.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|